Table 1.
Demographic, clinical characteristics and laboratory findings of SFTS patients
| Characteristics | SFTS (n = 6) |
|---|---|
| Epidemiology, no. (%) | |
| Age, mean Y ± SD (range) | 74.33 ± 10.97 |
| Female | 4 (66.7) |
| Occupational exposure | 2 (33.3) |
| Comorbidities, no. (%) | |
| Cardiovascular diseasea | 0 |
| Cerebrovascular disease | 0 |
| Pulmonary diseaseb | 0 |
| Chronic kidney disease | 0 |
| Diabetes mellitus | 1 (16.7) |
| Malignancies | 0 |
| Clinical signs and symptoms, no. (%) | |
| Headache | 2 (33.3) |
| Dyspepsia | 3 (50.0) |
| Nausea/vomiting | 3 (50.0) |
| Abdominal pain | 3 (50.0) |
| Chills | 5 (83.3) |
| Myalgia | 5 (83.3) |
| Fatigue | 5 (83.3) |
| Rash/eschar | 3 (50.0) |
| Tick bite | 3 (50.0) |
| Laboratory values, median (IQR) | |
| WBC count, ×1000/mm3 | 1.6 (1.2–2.4) |
| Platelet count, ×1000/mm3 | 100.0 (51.0–118.0) |
| aPTT, sec | 34.7 (27.8–44.0) |
| Total bilirubin, mg/dL | 0.35 (0.25–0.95) |
| Albumin, g/dL | 4.0 (3.6–4.7) |
| AST, IU/L | 148.5 (26.0–727.0) |
| ALT, IU/L | 104.0 (15.0–190.0) |
| LD, IU/L | 673.5 (421.0–1914.0) |
| Creatinine, mg/dL | 0.7 (0.5–1.3) |
| hs-CRP, mg/dL | 4.5 (0.2–13.7) |
| Clinical outcomes | |
| Length of hospital stay, median (IQR) | 9 (7.0–18.0) |
| In-hospital mortality, no. (%) | 2 (33.3) |
SFTS, severe fever with thrombocytopenia syndrome; SD, standard deviation; IQR, interquartile range; WBC, white blood cell; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LD, lactate dehydrogenase; CRP, C-reactive protein
aIncludes myocardial infarction, congestive heart failure, and peripheral vascular disease
bChronic obstructive pulmonary disease, asthma